Complix NV

Technologiepark 94

9052 Zwijnaarde

BE

Complix NV

Foundation date

23/06/2008

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Complix is a biopharmaceutical company engaged in the discovery and development of Alphabodies™, a revolutionary class of biopharmaceuticals with exceptional properties. Alphabodies™ combine beneficial properties of small molecules with those of antibodies, and can address intracellular as well as extracellular disease targets that are undruggable by antibodies or small chemical drugs. Complix has developed a balanced pipeline of transformative protein therapeutics in oncology, autoimmunity/inflammation and viral diseases.

Upcoming events

Latest news

  • Biotalys Appoints Kamal El Mernissi as Chief Business Development Officer

    Thursday October 17th 2024

  • InnoSer Announces Joint Initiative with Hasselt University/BIOMED to Support Preclinical Multiple Sclerosis Research

    Wednesday October 16th 2024

  • A brown ale or hoppy lager? Even fruit flies have a preference.

    Tuesday October 15th 2024